The 10 latest articles on Sickle Cell Disease come from 7 sources, published between Oct 30 and Nov 13. Most come from MarketScreener (3) and medicaldialogues.in (2).
People in these stories: Ashish Gupta (2), Haydar Frangoul (2)
Organizations: SCD (4), BLA (4), American Society of Hematology (4), FDA (3), Beam (3), EST Beam Therapeutics Inc. (2)
Places: New Orleans (4), U.S. (3), Africa (2), CT (2), United States (2)
Danish pharma major Novo today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European...
Written By: Dr. Kamal Kant Kohli Published On 2026-10-29T20:15:50+05:30 | Updated On 30 Oct 2026 12:36 PM IST Children living with sickle cell anaemia have no higher incidence of clinically diagnosed infections when treated with hydroxyurea. New research shows the efficacy and safety of hydroxyurea…
Written By: Dr. Aashi verma Published On 2026-11-13T21:00:02+05:30 | Updated On 13 Nov 2026 9:00 PM IST A recent diagnostic accuracy study published in the Indian Journal of Hematology and Blood Transfusion validates an innovative portable optical test for rapid sickle cell disease screening in…
Science News from research organizations Prime editing shows proof of concept for treating sickle cell disease Date: April 19, 2023 Source: St. Jude Children's Research Hospital Summary: Scientists showed how prime editing can correct mutations that cause sickle cell disease in a…
Beam Therapeutics said Tuesday its Beacon phase 1/2 study of ristoglogene autogetemcel, or risto-cel, in patients with sickle cell disease met its primary efficacy and safety endpoints at a... Biotechnology & Medical Research Beam Therapeutics Says Risto-Cel Meets Primary Endpoints in Sickle Cell…
Published on 11/10/2026 at 07:00 am EST Beam Therapeutics Inc. announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). Risto-cel is an investigational one-time, autologous cell…
Published on 11/04/2026 at 09:00 am EST Beam Therapeutics Inc. announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an oral presentation at the 68th American Society of…
November 4, 2026 at 9:00 AM EST PDF Version BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission…
Biotechnology Beam Sickle Cell Therapy Meets Pivotal Goals Ahead of Planned BLA Published November 10, 2026 By Anika Patel Genomics & Synthetic Biology, AI Research Agent Add Securities.io to your preferred sources on Google Beam Therapeutics (BEAM ) announced on November 10, 2026 that ristoglogene…
Sickle cell disease: patients' stories, gene therapies such as Casgevy, care and pain treatment, research and awareness campaigns.
An article joins this feed when it matches these terms. Each one is also a search of its own.